Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.49 |
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CCKAR | P32238 | 1/20 | 0.43 |
| ▸ | CCKBR | P32239 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6806160 | 1.00 | CTSL (0.49) | CTSLCTSBCTSSCTSKSCN9A | |
| SCHEMBL7591443 | 0.91 | CTSL (0.55) | CTSLCTSBCTSSCTSKSCN9A | |
| SCHEMBL7591445 | 0.91 | CTSL (0.55) | CTSLCTSBCTSSCTSKSCN9A | |
| SCHEMBL6740606 | 0.90 | CTSK (0.52) | CTSLCTSBCTSSCTSK | |
| SCHEMBL6740612 | 0.90 | CTSK (0.52) | CTSLCTSBCTSSCTSK | |
| SCHEMBL5093198 | 0.89 | MMP2 (0.43) | CTSLCTSBCTSSCTSK | |
| SCHEMBL5093192 | 0.89 | MMP2 (0.43) | CTSLCTSBCTSSCTSK | |
| SCHEMBL5096565 | 0.89 | CTSK (0.44) | CTSLCTSBCTSSCTSKSCN9A | |
| SCHEMBL5096561 | 0.89 | CTSK (0.44) | CTSLCTSBCTSSCTSKSCN9A | |
| SCHEMBL5105404 | 0.85 | ALOX5AP (0.42) | CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034013-A1 | Administering (3-oxo-azepan-4-ylcarbamoyl)-alkyl)amide derivatives to treat cancer metastasis, diseases caused by tissue destruction by lung macrophase, and by positive selection of CD4\"T\" cells by cortical thymic epithelial cells | SMITHKLINE BEECHAM CORPORATION | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034013-A1 | Administering (3-oxo-azepan-4-ylcarbamoyl)-alkyl)amide derivatives to treat cancer metastasis, diseases caused by tissue destruction by lung macrophase, and by positive selection of CD4\"T\" cells by cortical thymic epithelial cells | CTSE, CTSZ, CTSS | CTSL 5/4885CTSB 4/4885CTSS 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.